Please assess the completion status of the following clinical trial:

Trial Title: COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age;~* laboratory or clinical-epidemiological confirmation of COVID-19 (history of close or home contact with a laboratory-confirmed case who has fever or at least one of the respiratory signs or symptoms, in the last 14 days after contact, and for which it was not possible to carry out the specific laboratory investigation)~Exclusion Criteria:~* Immunosuppressed patients of any kind;~* Pregnant women;~* More than 14 days from the onset of symptoms;~* Not accept participation or non-signature of the IC;~* Undiagnosed cases, suspected or probable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCG vaccine (Type: ACTIVE_COMPARATOR): BCG Group (n = 200): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group (n = 200): 0.9% saline solution in the same volume as BCG vaccine in a single dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).